ABBA Therapeutics closed ”Seed B” financing round Basel, Switzerland - 20.08.2018 - ABBA Therapeutics successfully closed “Seed B” financing round with European investors. The raised fund will be used to accelerate the preclinical efficacy study with cutting-edge animal models and advance two lead candidates for clinical efficacy study. About ABBA Therapeutics ABBA Therapeutics is a [...]

ABBA Therapeutics was selected for BaseLaunch program Basel, Switzerland - 18.09.2017 - ABBA Therapeutics was selected to participate BaseLaunch program from more than 100 international applications. ABBA Therapeutics will receive non-dilutive funding CHF 10,000 for continuing its pipeline development. About ABBA Therapeutics ABBA Therapeutics is a Swiss biotechnology company founded in Basel in 2016. ABBA [...]

ABBA Therapeutics enters into OmniAb® Platform License Agreement With Ligand Basel, Switzerland - 28.03.2016 - ABBA Therapeutics AG announces it has entered into a worldwide license agreement with Ligand Pharmaceuticals (NASDAQ: LGND). Under this agreement, ABBA Therapeutics will use OmniAb® platform, an industry-leading technology including OmniRat®, OmniMouse® and OmniFlic®, to generate fully human mono- and [...]